Radiodermatitis can be classifiedas acute or chronic. The acute condition occurs within 90 days of exposure toradiation, whereas the chronic condition may occur from 15 days to 10 years ormore after the beginning of radiation therapy. Topical products, oralmedications, and dressings are used in the treatment and management ofradiodermatitis.
The global RadiodermatitisMarket is estimated to account for US$ 360.5 Mn in terms of value and isexpected to reach US$ 472.8 Mn by the end of 2027.
Global Radiodermatitis Market:Drivers
High risk of chronicradiodermatitis after fluoroscopically guided interventions is expected topropel growth of the global radiodermatitis market over the forecast period.For instance, according to the study, ‘Incidence of Chronic Radiodermatitisafter Fluoroscopically Guided Interventions: A Retrospective Study’, publishedin the Journal of Vascular and Interventional Radiology in May 2019, 8.8% ofthe patients adopting fluoroscopically guided interventions suffered fromchronic radiodermatitis.
Global Radiodermatitis Market:Opportunities
Lack of definitive/standardtreatment creates ambitious avenue for a breakthrough, thereby offeringlucrative growth opportunities for players in the global radiodermatitismarket. Radiation dermatitis symptomsare typically managed with a variety of topical agents such as water-basedmoisturizing creams or lotions, topical steroids, anti-inflammatory emulsions,and wound dressings. However, even with these options, there is no standardtreatment currently for the prevention of radiation-induced dermatitis withproven effectiveness. This leads to a tremendous opportunity for theintroduction of a breakthrough treatment, which can be considered as standardcare and effective in the amelioration of radiation-induced skin damage.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3881
Global Radiodermatitis Market:Restraints
Stringent regulatory scenario isexpected to hinder growth of the market. Treatment products for radiationdermatitis are required to undergo clinical trials and approval by regulatorybodies. Conducting trials and filing for approval for novel innovations is atime-consuming process and also requires substantial financial investment. Thetermination or inefficacy to get a standard treatment through certain studiespertaining to this market could create a deterrent for new players, which couldrestrain growth of the market.
Key Takeaways:
The global radiodermatitis marketwas valued at US$ 346.9 Mn in 2019 and is forecast to reach a value of US$472.8 Mn by 2027 at a CAGR of 3.9% between 2020 and 2027. Major factor drivingthe growth of global radiodermatitis market during the forecast periodincreasing prevalence of cancer, and product launches and approvals forRadiodermatitis treatment.
Topical agents held dominantposition in the global radiodermatitis market in 2019, accounting for 70.5%share in terms of value, followed by dressing and oral medication,respectively. Ease of application of topical agents is expected to supportgrowth of the segment.
Retail pharmacies segment held dominant position in theglobal radiodermatitis market in 2019, accounting for 38.9% share in terms ofvalue.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/radiodermatitis-market-3881
Market Trends
In New Zealand, Swedishsilicon-foam skin dressing, Mepilex Lite (Mölnlycke Health Care, Sweden) is usedfor the treatment of burns and slow healing wounds. Silver-leaf nylon dressinghas proven to have effective antimicrobial activity and enhances healing inburns and skin grafts. Non-adherent dressings such as silicone dressing and nosting barrier film dressings are also recommended for the treatment ofradiodermatitis.
E-commerce is a majordistribution channel in the market. For instance, 3M offers Cavilon no stingbarrier film for online sale on its official website as well as retail websitessuch as Amazon. RadX, Stratpharma, Molnlycke Health Care, Medline Industries,and Advancis Medical are key players in this market that have their majorproducts available online.
Global Radiodermatitis Market:Competitive Landscape
Major players operating in theglobal radiodermatitis market include, Acelity, Inc. (3M), BMG Pharma S.r.l.,ConvaTec Group PLC, DermaSciences Inc. (Integra LifeSciences HoldingsCorporation), Intermed Pharmaceuticals, Molnlycke Health Care, Smith & NephewPlc, Stratpharma AG, Kannalife, Inc., and Jay Pharma
Global Radiodermatitis Market:Key Developments
September 2019: ConvaTec GroupPlc signed an agreement to purchase the assets of Southlake Medical Supplies,Inc., a U.S.-based independent provider of catheter-related supplies
July 2019: Integra LifeSciencesHoldings Corporation acquired Arkis Biosciences Inc., a privately-held companythat offers a portfolio of neurosurgical devices
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3881
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
